Evidence map›Paper›PMID 37182637›Full record

ArticleClinical biochemistry2023

Proof of concept: Detection of cell free RNA from EDTA plasma in patients with lung cancer and non-cancer patients.

Kristin E Mullins, Chamindi Seneviratne, Amol C Shetty, Feng Jiang, Robert Christenson, Sanford Stass

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kristin E MullinsDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA; Laboratories of Pathology, University of Maryland Medical Center, Baltimore, MD, USA. Electronic address: kmullins@som.umaryland.edu.
Chamindi SeneviratneDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; The Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Amol C ShettyThe Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Feng JiangLaboratories of Pathology, University of Maryland Medical Center, Baltimore, MD, USA.
Robert ChristensonDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA; Laboratories of Pathology, University of Maryland Medical Center, Baltimore, MD, USA.
Sanford StassDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA; Laboratories of Pathology, University of Maryland Medical Center, Baltimore, MD, USA.
University of Maryland, Baltimore · US

Funding

Optimizing Ultrasensitive DNA methylation detection for lung cancer and other malignanciesU2CCA271885 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JAMES G. HERMAN · 2022 to 2026
$4.2M
Genomic Predictors of Placebo response in Phase II AUD trialsR01AA026291 · NIAAA · UNIVERSITY OF MARYLAND BALTIMORE · PI MAHURKAR, ANUP · 2018 to 2022
$2.9M
Biomarkers to Measure Treatment Response for Alcohol DependenceK23AA020899 · NIAAA · UNIVERSITY OF VIRGINIA · PI SENEVIRATNE, CHAMINDI · 2012 to 2016
$741k
FDA HHS U01 FD005946NCI NIH HHS U2C CA271885NIAAA NIH HHS K23 AA020899NIAAA NIH HHS R01 AA026291
6 · The paper itself

Abstract

introductionNucleic acid sequencing technologies have advanced significantly in recent years, thereby allowing for the development of liquid biopsies as new means to detect cancer biomarkers and cancer heterogenicity. Most of the assays available, clinically, focus on cell free DNA (cfDNA), however, cell free RNA (cfRNA) is also present. cfRNA has the potential to complement and improve cancer detection especially in cancers like lung cancer, which are usually only diagnosed at late stages and therefore have poor long-term survival outcomes.

methodsRemnant EDTA plasma was collected from lung cancer patients and non-cancer individuals at the University of Maryland Medical Center. RNA was extracted and processed for next generation sequencing with a tagmentation-based library preparation approach.

resultscfRNA was successfully extracted and sequenced from 52 EDTA-treated plasma samples with volumes as low as 1.5 mL. This quantity was sufficient to prepare libraries with the length of libraries averaging from 264 bp to 381 bp and resulted in over 2.2 to 3.6 million total sequence reads respectively. Sequential dilution of cfRNA samples from healthy individuals indicated that the starting cfRNA concentration influenced the detection of differentially expressed genes.

conclusionsThis proof-of-concept study provides a framework for screening cfRNA for identifying biomarkers for early detection of lung cancer (and other cancers), using minimal amounts of samples (1.5 mL) from standard EDTA 3-mL collection tubes routinely used for patient care. Further studies in large populations are required to establish limit of detection and other parameters including precision, accuracy, sensitivity, and specificity, to standardize this method.

Indexed as

Cell-Free Nucleic AcidsLung NeoplasmsBiomarkers, TumorDNA, NeoplasmEdetic AcidHumansLiquid BiopsyBiomarkers, TumorCell-Free Nucleic AcidsDNA, NeoplasmEdetic AcidCell-free DNACell-free RNALiquid biopsyLung cancerNext generation sequencing

Identifiers

PMID37182637
PMCPMC12183646
OpenAlexW4376254211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.